Akeso, Inovio Partner on GBM Therapy in Adaptive Trial
Event summary
- Akeso (HKEX: 9926.HK) and Inovio (NASDAQ: INO) are collaborating on a Phase II clinical trial to evaluate Akeso’s cadonilimab in combination with Inovio’s INO-5412 for glioblastoma (GBM).
- The trial will be conducted within the INSIGhT adaptive platform trial sponsored by the Dana-Farber Cancer Institute.
- Dosing in the combination therapy trial is expected to begin in the second half of 2026.
- Cadonilimab is already approved in China for several cancer indications and is part of over 11 Phase III/registration clinical studies.
The big picture
The collaboration reflects the growing trend of combining immunotherapy approaches to overcome treatment resistance in aggressive cancers like GBM. Akeso’s established bispecific antibody platform, coupled with Inovio’s DNA immunotherapy, represents a strategic bet on a synergistic therapeutic effect. The INSIGhT adaptive trial design aims to accelerate the evaluation of this combination, a crucial factor given the limited treatment options and high unmet need in GBM.
What we're watching
- Clinical Efficacy
- The success of the INSIGhT trial will hinge on demonstrating a meaningful survival benefit for GBM patients, a notoriously difficult-to-treat cancer, and will be a key catalyst for both Akeso and Inovio.
- Regulatory Pathway
- Given cadonilimab’s existing approvals in China, the regulatory pathway in other markets will be crucial; the INSIGhT trial’s data will heavily influence future submissions.
- Commercialization
- The partnership's ability to navigate the complexities of commercializing a novel combination therapy, particularly in a high-cost oncology setting, will determine the long-term financial viability of the collaboration.
Related topics